Name: Elesclomol (STA-4783)
Price: 228.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Elesclomol (also known as STA-4783), originally identified in a cell-based phenotypic screen for proapoptotic activity, is a novel small-molecule that potently induces apoptosis of cancer cells through the rapid generation of reactive oxygen species (ROS) and the induction of unmanageable levels of oxidative stress. Elesclomol exhibits autitumor activity against a broad spectrum of types of cancer cell in human tumor xengograft models due to its excessive ROS production and elevated levels of oxidative stress leading to the death of cancer cells. Elesclomol is currently being studies as a novel cancer therapeutic, in which it has demonstrated ability to prolong progression-free survival in study subjects.
    
    Reference:
    Ronald K. Blackman, Kahlin Cheung-Ong, Marinella Gebbia, David A. Proia, Suqin He, Jane Kepros, Aurelie Jonneaux, Philippe Marchetti, Jerome Kluza, Patricia E. Rao, Yumiko Wada, Guri Giaever, Corey Nislow. Mitochondrial electron transport is the cellular target of the oncology drug elesclomol. PLoS ONE 2012; 7(1): e29798
    Jessica R. Kirshner, Suqin He, Vishwasenani Balasubramanyam, Jane Kepros, Chin-Yu Yang, Mei Zhang, Zhenjian Du, James Barsoum, and John Bertin. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther 2008; 7:2319-2327
- Properties
  - Categories
    
    Oxidative stress/apoptosis inducer, potent and novel
    
    Alternative Name
    
    STA 4783, STA4783; 1-N',3-N'-bis(benzenecarbonothioyl)-1-N',3-N'-dimethylpropanedihydrazide
    
    CAS Number
    
    488832-69-5
    
    Molecular Formula
    
    C19H20N4O2S2
    
    Molecular Weight
    
    400.5
    
    Appearance
    
    A solid
    
    Purity
    
    98.00%
    
    Solubility
    
    insoluble in H2O; ≥20.15 mg/mL in DMSO; ≥5.68 mg/mL in EtOH with gentle warming and ultrasonic
    
    Storage
    
    Store at -20°C
    
    SMILES
    
    CN(C(=S)C1=CC=CC=C1)NC(=O)CC(=O)NN(C)C(=S)C2=CC=CC=C2
    
    * For Research Use Only
- Reference
  - 1. Albayrak G, Korkmaz FD, et al. "The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol." J Cell Biochem. 2019 Jan 10. PMID:30628735
    2. Li H, Guo S, et al."Lipopolysaccharide and heat stress impair the estradiol biosynthesis in granulosa cells via increase of HSP70 and inhibition of smad3 phosphorylation and nuclear translocation." Cell Signal. 2017 Jan;30:130-141. PMID:27940052
    3. Ali A. Alshamrani, James L. et al. "Inhibiting Lactate Dehydrogenase A Enhances the Cytotoxicity of the Mitochondria Accumulating Antioxidant, Mitoquinone, in Melanoma Cells." Human Skin Cancer, Potential Biomarkers and Therapeutic Targets.October 19th 2016.

Documents

COA (Certificate Of Analysis)

MSDS (Material Safety Data Sheet)

Datasheet

Elesclomol (STA-4783)

Elesclomol (STA-4783)

Background

Documents

We Also Recommend

Pemetrexed

VER 155008

XL-888